|
Oct 03 2024
Parkinson’s therapy safely increases GCase activity in healthy volunteers
Parkinson's News Today
|
|
Sep 03 2024
Gain readies for Phase 1b trial of Parkinson’s therapy GT-02287
Parkinson's News Today
|
|
Aug 30 2024
Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
Clinical Trials Arena
|
|
Aug 30 2024
In the clinic for Aug. 30, 2024
BioWorld
|
|
Aug 29 2024
GCase-Targeting Parkinson Drug GT-02287 Shows Target Engagement, Encouraging Safety in Early-Stage Study
Neurology Live
|
|
Aug 29 2024
Gain hopes to prove Parkinson's drug's potential next year after phase 1 win for allosteric modulator
Fierce Biotech
|
|
Aug 13 2024
A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
PharmaVoice
|
|
Jul 15 2024
Breaking the Cycle of Inflammation in Parkinson’s Disease
BioSpace
|
|
Jul 04 2024
Parkinson’s disease: biotech’s pursuit for more therapies
Labiotech
|
|
Jul 02 2024
GT-02287 aids motor, cognitive function in GBA1 Parkinson’s mice
Parkinson's News Today
|
|
Jul 02 2024
Gain's clinical GDP1 Parkinson's drug helps mice retain cognitive function
Fierce Biotech
|
|
Jun 28 2024
Meet the Researcher: Dr. Joanne Taylor
DDW
|
|
Jun 24 2024
Gain Therapeutics Navigates Market Fluctuations While Developing Parkinson’s Treatment
In Vivo Citeline Commercial
|
|
May 28 2024
Gain biotech CFO aims past burn to budget for growth
CFO DIVE
|
|
May 09 2024
Dr. Jonas Hannestad - CMO, Gain Therapeutics - Transforming Treatment Of Neurodegenerative Diseases
Youtube
|
|
Apr 25 2024
In the clinic for April 25, 2024
BioWorld
|
|
Apr 25 2024
Gain touts positive Phase I results for Parkinson’s therapy
ClinicalTrial
|
|
Apr 22 2024
Using AI to Create New Parkinson’s Treatments: Q&A with Matthias Alder
Pharmaceutical Executive
|
|
Apr 19 2024
Doug Williams leaving Sana Plus: Baptista joins SmartCella and updates from LifeArc and Gain
BioCentury
|
|
Apr 11 2024
Recent pharma industry appointments that should be on your radar
Outsourcing Pharma
|
|
Apr 01 2024
Gain Therapeutics gets new chief medical officer
Seeking Alpha
|
|
Mar 21 2024
Data Showcases Promising Mechanism of Action of GT-02287 for Parkinson Disease
NeurologyLive
|
|
Mar 07 2024
Cell, mouse models of Parkinson’s disease give data on GT-02287
Parkinson's News Today
|
|
Mar 06 2024
Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
Benzinga
|
|
Mar 05 2024
Phase 1 trial of therapy for GBA1 Parkinson’s advances in dosing
Parkinson's News Today
|
|
Feb 28 2024
Swiss biotech restores motor function in mice with Parkinson’s disease
c&en
|
|
Feb 14 2024
Data shows restored motor function in mouse models of Parkinson’s disease
Drug Discovery World
|
|
Feb 14 2024
Gain Therapeutics’ supercomputer-driven therapy offers potential Parkinson’s breakthrough
Drug Discovery Trends
|
|
Feb 06 2024
Gain's clinical Parkinson's drug restores motor function in mice
Fierce Biotech
|
|
Feb 08 2024
Motor function restored in Parkinson’s mice with GT-02287
Parkinson's News Today
|
|
Jan 29 2024
Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhD
Neurology Live
|
|
Jan 04 2024
POWER OF SUPERCOMPUTING AND AI: REVOLUTIONIZING ALLOSTERIC DRUG DISCOVERY
bio-itworld
|
|
Oct 23 2023
The Potential of Neurofilament Light Chain as a Biomarker in Parkinson’s Disease
BioSpace
|
|
Oct 11 2023
Allosteric therapy targets common genetic cause of Parkinson’s
Drug Discovery World
|
|
Oct 10 2023
Dosing Underway for Phase 1 Parkinson Trial of GBA1-Targeting Agent GT-02287
Neurology Live
|
|
Oct 02 2023
Parkinson’s Research Buoyed by Alzheimer’s Advances
BioSpace
|
|
Sep 27 2023
Allosteric drugs: A differentiated small molecule approach
Drug Discovery & Development
|
|
Sep 15 2023
Gain Therapeutics cleared to start GT-02287 Phase 1 trial in Australia
Parkinson’s News Today
|
|
Sep 15 2023
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
Precision Medicine Online
|
|
Sep 13 2023
Gain Therapeutics receives Australian HREC approval to begin phase I study of GT-02287 for GBA1-Parkinson’s disease
BioWorld
|
|
Aug 30 2023
Gain Therapeutics: Tackling Rare Diseases at the Genetic Level
Nasdaq
|
|
Aug 29 2023
Oral therapy GT-02287 shows promise in Parkinson’s mice models
Parkinson’s News Today
|
|
Aug 25 2023
The Future Is Now: Matthias Alder Of Gain Therapeutics On How Their Technological Innovations Will Shake Up The Tech Scene
The Authority Magazine
|
|
Dec 02 2021
Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease
BioSpace
|
|
Nov 12 2021
STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s
Parkinsons News Today
|
|
Oct 01 2021
A New Approach to Protein Misfolding in Parkinson Disease
Neurology Live
|
|
Sep 13 2021
Small Molecules, STARs Treat Cell Models of GBA1-linked Parkinson’s
Parkinsons News Today
|
|
Sep 12 2021
Gain Therapeutics' SEE-Tx™ Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding
Benzinga
|
|
Sep 08 2021
Positive Topline Results for Novel Parkinson's Treatment
Medscape Medical News
|
|
Apr 27 2021
Direct Listing vs. IPO
US News
|
|
Apr 27 2021
Gain Therapeutics Raises $40M in IPO to Advance Rare Disease Pipeline
RareDaily
|
|
Mar 18 2021
Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint
Nasdaq
|
|
Feb 02 2021
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
pm360
|
|
Sep 28 2020
Treating lysosomal storage disorders: Gain and Sumitomo Dainippon enter partnership
Pharmaceutical Technology
|
|
Sep 10 2020
Gain Therapeutics Inc. signs a collaboration with Sumitomo Dainippon Pharma Co. Ltd.
BioWorld
|
|
Jul 21 2020
Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
BioSpace
|
|
Feb 10 2020
Gain Therapeutics finalizing animal proof-of-concept study in Parkinson's Disease
Proactive
|
